Skip to main content
. 2018 Feb 2;9(13):11279–11290. doi: 10.18632/oncotarget.24397

Table 1. Patient characteristics.

Patient No. T stage N stage No. nodes Max node size (centimeters) Chemo Primary tumor site HPV status Disease status
1 2 2c 5 3 q 3 weeks CDDP tongue base positive no recurrence
2 2 2b 4 3.8 q 3 weeks CDDP tonsil positive no recurrence
3 2 2c 5 4.9 q 3 weeks CDDP tongue base positive no recurrence
4 4a 1 1 2.3 q 3 weeks CDDP tongue base positive no recurrence
5 2 2a 1 3 q 3 weeks CDDP tonsil positive no recurrence
6 2 2b 2 2.9 q 3 weeks CDDP tonsil positive no recurrence
7 1 2b 2 2.6 q 3 weeks CDDP tongue base positive no recurrence
8 x 2b 2 3.6 q 3 weeks CDDP unknown negative no recurrence
9 1 2b 2 3.8 Weekly CDDP tongue base positive no recurrence
10 x 2b 2 1.9 Weekly CDDP unknown negative no recurrence
11 4a 2b 3 6 Weekly CDDP tonsil positive no recurrence
12 1 2b 2 2.4 Weekly CDDP tonsil positive no recurrence
13 2 3 7 8 Weekly CDDP base tongue positive no recurrence
14 1 2b 3 2.2 weekly cetuximab tongue base negative Persistent disease in right neck, salvaged with surgery. Second local recurrence in right neck, treated with SBRT. Third recurrence, on anti-PD1 therapy with partial response
15 x 3 6 6.5 weekly cetuximab unknown Positive rapid recurrence, passed away

Abbreviations: HPV, human papilloma virus; CDDP, cisplatin; SBRT, stereotactic body radiation therapy.